Table 1.

Baseline characteristics.

	Nonrare (N = 336)	Rare (N = 164)	Total (N = 500)	P
Age at consent (IQR)	64 (55–71)	61 (49–68)	63 (53–70)	<0.001a
Gender (%)
Male	166 (49%)	103 (63%)	269 (54%)	0.006b
Female	170 (51%)	61 (37%)	231 (46%)
WHO PS (%)
WHO 0	90 (30%)	51 (35%)	143 (32%)	0.229c
WHO 1	186 (61%)	89 (60%)	275 (61%)
WHO 2	25 (8%)	8 (5%)	33 (7%)
Previous systemic therapy lines (IQR)	3 (2–5)	2 (1–3)	3 (2–5)	<0.001a
Previous chemotherapy lines (IQR)	2 (1–3)	1 (0–3)	2 (1–3)	<0.001a
Previous hormonal therapy lines (IQR)	0 (0–1)	0 (0–0)	0 (0–0)	NA
Previous immunotherapy lines (IQR)	0 (0–1)	0 (0–0)	0 (0–1)	NA
Previous targeted therapy lines (IQR)	0 (0–0)	0 (0–0)	0 (0–0)	NA

Note: Baseline characteristics of enrolled patients in the DRUP trial: rare versus nonrare cancer types.

Abbreviations: IQR, interquartile range; NA, nonapplicable; WHO PS, World Health Organization Performance Status.

^aKruskal–Wallis ranks sum test.

^bFisher exact test for count data.

^cTrend test for ordinal variable.